Oryzon to partner before market entry

Spanish biopharmaceutical company Oryzon Genomics develops epigenetic personalized medicines for patients with cancer and CNS disorders.

BioStock met with CEO Carlos Buesa at this week’s BIO-Europe conference. He talked about their plans to pursue a phase III trial in Borderline Personality Disorder, and, as for the conference, he alluded to multiple interactions with potential partners.